The Technical Story of Rocket Pharmaceuticals Inc (RCKT) Stock
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Stock lower -15.48% in This Year: What’s Happened?
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
Rocket Pharmaceuticals Inc (RCKT) Stock offers help to cash-strapped investors
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
A good growth outlook is seen for Rocket Pharmaceuticals Inc (RCKT) Stock by analysts
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
A New Look at Rocket Pharmaceuticals Inc (RCKT) Stock’s Hidden Strategies
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock is trading 34.05 percent above its 52-week low
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
Faced with a depressed economy, Rocket Pharmaceuticals Inc (RCKT) Stock offers an opportunity
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
What do you think? Take A Moment To Read: Rocket Pharmaceuticals Inc (RCKT) Stock
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
The future looks bright for Rocket Pharmaceuticals Inc (RCKT) Stock
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
Earnings and valuation of Rocket Pharmaceuticals Inc (RCKT) Stock are impressive
Goldman raised the price target for the Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock to “a Neutral”. The rating was released on April 02, 2024, according to finviz. The research report from Morgan Stanley has initiated the stock to Overweight, with a price target set at $45. The stock was initiated by Canaccord Genuity, who disclosed in […]
